The research area is characterized by innovative research aimed towards discovery and development of new therapeutic agents from plants and other natural sources, and development of new and improved research technologies and methodologies within the field. The group combines modern technologies and pioneering visions with strong traditions for research in natural products, characteristic for the pharmaceutical universe, with the overall aim to improve human health and disease control.
Visions
The missions of the central research area are to:
• Provide cutting edge technology for drug discovery based on natural resources • Provide new lead compound for medicinal chemistry research • Provide knowledge and services to the Society in relation to the use of natural products as drugs, natural remedies, and food supplements
Traditionally, natural products have served as a major source of drugs. In the recent decade, the rate of launching of new drugs has stagnated and in 2005 decreased to an alltime low. At the same time, there is a growing understanding that natural products are a source of chemical diversity and biological functionality, which are inaccessible by other means. New technologies, such as high-throughput dereplication based on hyphenated techniques (e.g., HPLC-SPE-NMR), diversity-oriented synthesis of natural products libraries, natural product scaffolds, multivariate analysis of complex spectroscopic and chromatographic data, genetic engineering, and combinatorial biosynthesis, provide basis for a renewed interest in natural products in big pharmaceutical companies. At the same time, numerous start-up companies bring natural product-based, experimental drugs into clinical trials.
Our visions are to advance our position as a major European research group in the natural product field, promote natural products-based drug discovery programs in the pharmaceutical industry through research in underlying technologies, and to promote rational and knowledge-based use of natural remedies by the consumers. 
Importance to the society
The importance of the research area to the society is manifested at many levels, first and foremost through generation of knowledge within this important field, but also through education of pharmacists and researchers, who receive interdisciplinary training. Candidates graduating from the group are in strong demand in the Danish pharmaceutical industry. Natural products and natural products-derived drugs are of great importance to the society. The group contributes to the European Pharmacopeia, and supports work of Danish Drug Administration related to natural products.
The area of natural products research has contributed with a major part of the patents issued at DFU. One of a very few start-up companies, established or co-established by researchers from DFU, originates from research in this group (Lica Pharmaceuticals).
The group has collaboration-or service-agreements with 6 industrial partners.
Collaborations (defined by co-publications)
International Author or coauthor on 123 articles in scientific journals, coeditor on 2 books and coinventor on 6 patents.
In 1975 S. Brøgger Christensen (SBC) initiated work on natural products chemistry with emphasis on biologically active natural products. In 1978 the first paper on the SERCA inhibitor thapsigargin, which has become a standard tool for studies on calcium homeostasis, was published. Since 1978 SBC have been engaged in isolation, structure elucidation and biological evaluation of thapsigargin and naturally occurring analogues of thapsigargin and in systematic semisynthetic changes of thapsigargin in order to elucidate the structure activity relationships. In 1988 SBC published the generally accepted structure of thapsigargin. Presently prodrugs of thapsigargin are prepared in order to develop drugs for treatment of prostate cancer. Analogues with high affinity for the thapsigargin binding site on the Sarco/endoplasmic reticulum ATPase have been designed and synthesized. In 1989/90 SBC extended his studies to enclose natural products usable for treatment of tropical diseases. A number of molluscicidal coumarins and saponins have been isolated and structure elucidated. Some antiparasitic chalcones have been isolated. Analogues are prepared and medicinal chemical studies are undertaken to optimise the antiparasitic activities. The work on chalcones formed a part of the intellectual properties behind the formation of the biotechnological company Lica Pharmaceuticals A/S. Neolignans have been synthesized and tested for antiplasmodial acitivities. Studies on rose hips (Rosa canina) has revealed the presence of an antiinflammatoric lipid, which might explain the clinically observed rheumatic pain releasing effect of the drug. 
Memberships

Member of the Subcommittee on Pharmacognosy, The Danish Pharmacopoeia Commission
Publications 30 articles in peer-reviewed journals and more than 20 articles dealing with herbal remedies. 
Research interests
In general my research interests are total synthesis of natural products and the utilization of natural products as starting materials or as chiral-pool building blocks in the synthesis of compounds with a potential biological activity. Currently, my main research projects comprise the development of novel solid-phase organic chemistry procedures and their application in structure-activity relationship (SAR) studies of analogues af biologically active lead compounds obtained from natural sources.
